Bhattacharya Anasua, Syamlal Girija, Dodd Katelynn E
Respiratory Health Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Cincinnati, Ohio, USA.
Respiratory Health Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, West Virginia, USA.
Am J Ind Med. 2024 Sep;67(9):834-843. doi: 10.1002/ajim.23633. Epub 2024 Jul 3.
BACKGROUND: Asthma, a chronic respiratory disease, is associated with high economic burden. This study estimates per-worker medical and incremental medical costs associated with treated asthma by socioeconomic and demographic characteristics, industries, medical events, and sources of payments for workers aged ≥18 years. METHODS: We analyzed Medical Expenditure Panel Survey data from 2018 to 2020 to assess medical costs for treated asthma among workers using the International Classification of Diseases, Tenth Revision, Clinical Modification code for asthma (J45). We used two-part regression models to estimate medical and incremental medical costs controlling for covariates. All results are adjusted for inflation and presented in 2022 US dollar values. RESULTS: An estimated annual average of 8.2 million workers out of 176 million had at least one medical event associated with treated asthma. The annualized estimated per-worker incremental medical costs for those with treated asthma was $457 and was highest among: those in the age group of 35-44 years ($534), in the western region ($768), of Hispanic ethnicity ($693), employed in the utility and transportation industries ($898), males ($650), and for inpatient admissions ($754). The total annualized medical costs of treated asthma was $21 billion and total of incremental medical costs was $3.8 billion. CONCLUSION: Findings of higher incremental medical costs for treated asthma among workers in certain socioeconomic, demographic, and industry groups highlight the economic benefit of prevention and early intervention to reduce morbidity of asthma in working adults. Our results suggest that the per-person incremental medical costs of treated asthma among workers are lower than that for all US adults.
背景:哮喘作为一种慢性呼吸道疾病,会带来高昂的经济负担。本研究按社会经济和人口特征、行业、医疗事件以及支付来源,估算了18岁及以上工人因接受哮喘治疗而产生的人均医疗费用和额外医疗费用。 方法:我们分析了2018年至2020年的医疗支出面板调查数据,以使用国际疾病分类第十次修订本临床修订版哮喘代码(J45)评估工人中接受哮喘治疗的医疗费用。我们使用两部分回归模型来估算控制协变量后的医疗费用和额外医疗费用。所有结果均经通货膨胀调整,并以2022年美元价值呈现。 结果:在1.76亿工人中,估计每年平均有820万工人至少有一次与接受哮喘治疗相关的医疗事件。接受哮喘治疗的工人的年化人均额外医疗费用为457美元,在以下人群中最高:35 - 44岁年龄组(534美元)、西部地区(768美元)、西班牙裔(693美元)、受雇于公用事业和运输行业(898美元)、男性(650美元)以及住院治疗(754美元)。接受哮喘治疗的年度总医疗费用为210亿美元,额外医疗费用总计为38亿美元。 结论:某些社会经济、人口和行业群体的工人中,接受哮喘治疗的额外医疗费用较高,这一发现凸显了预防和早期干预对降低在职成年人哮喘发病率的经济效益。我们的结果表明,工人中接受哮喘治疗的人均额外医疗费用低于所有美国成年人。
Ann Am Thorac Soc. 2018-3
MMWR Morb Mortal Wkly Rep. 2020-7-3
JAMA Dermatol. 2019-6-1
Am J Respir Crit Care Med. 1997-9
Osteoarthritis Cartilage. 2017-12-18
Ann Allergy Asthma Immunol. 2025-7
MMWR Surveill Summ. 2021-9-17
J Asthma Allergy. 2020-10-29
MMWR Morb Mortal Wkly Rep. 2020-7-3
J Korean Med Sci. 2019-3-7
Allergy Asthma Immunol Res. 2019-3
Ann Am Thorac Soc. 2018-3
Anaesth Crit Care Pain Med. 2015-5-16
BMC Health Serv Res. 2015-4-3